Navigation Links
Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
Date:9/6/2012

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

According to the American Cancer Society, lung cancer is the number one cause of cancer deaths in men and women each year. The current standard treatment for advanced NS-NSCLC patients, the most common form of advanced NSCLC, is either Pac+Cb+B or pemetrexed plus cisplatin. This trial sought to define a new standard of care by comparing Pac+Cb+B to the experimental chemotherapy regimen Pem+Cb+B to determine if either improved overall survival for late-stage lung cancer patients. Pemetrexed plus cisplatin was not tested in this trial.

The 939 patients were randomized to receive one of the two treatment arms every three weeks for up to four cycles. The patients received the same arm for each cycle. Overall survival was not statistically different between the two arms, 12.6 months in Pem+Cb+ Bev versus 13.4 months for the Pac+Cb+B arm, The experimental arm of Pem+Cb+Bev led to a increase in time before progression of disease (PFS) compared with the standard arm of Pac+ Cb+Bev6 months versus 5.6 months, respectively.

"The fact that there was no improvement in survival with the experimental regimen was disappointing, but these findings are important as we continue to navigate ways to improve survival for this devastating disease," said Jyoti Patel, MD, lead author of the study and an associate professor in Medicine-Hematology/Oncology at Northwestern University in Chicago. "It is important to note that both regimens demonstrated tolerability, although their toxicities differed. These differences can be important for our patients."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Job injuries among youth prompt calls for better safety standards
2. Can a standard vision test predict nighttime driving performance?
3. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
4. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
5. New standards for treating traumatic shoulder injuries to improve patient care
6. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
7. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
8. First, do no harm: Study finds danger in standard treatment for a serious lung disease
9. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
10. Standard Process Inc.’s Marketing Team Wins Six Awards
11. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... “Vinaya” Rednam distinguishes herself once more by being among Houston’s first plastic surgeons ... the highest quality plastic surgery care without disrupting busy schedules and maintaining the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida Hospital Zephyrhills showcased ... community partners. The newly renovated ER was designed with patients in mind and ... semi-private rooms to deliver patient results, improve efficiencies and reduce length of stay, ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new features, ... changes to the smartwatch market. As of June 2017, nearly nine percent of U.S. ... months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from NPD’s ...
(Date:8/17/2017)... ... 17, 2017 , ... Pot Valet is a leading provider of premium medical-grade ... the state, and soon, every state in the country, the company offers patients safe, ... dispensary altogether. , According to Pot Valet, all California patients have the ...
(Date:8/17/2017)... VA (PRWEB) , ... August 17, 2017 , ... ... for Great Employers , an international competition, were announced today. The awards recognize ... products and suppliers who help to create and drive great places to work. ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST ) ... and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a ... sales at constant currency (organic) grew by 3.9%. ... to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology: